Guardant Health Inc.
Roberto A. Mignone Joins Guardant Health Board of Directors
Summary
Guardant Health, Inc. announced on October 21, 2024, the appointment of Roberto A. Mignone as a new Class I director to its Board, effective immediately. Mr. Mignone, Founder and Managing Partner of Bridger Management LLC, will serve on the Board until the 2025 Annual Meeting of Stockholders. He was also appointed to the audit committee of the Board. His compensation includes stock option and restricted stock unit awards, each valued at $362,500, and he will be indemnified by the Company. The appointment was further announced in a press release on October 24, 2024.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement